PROKIDNEY CORP (PROK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.01+4.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PROK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PROK — earnings miss
Dated 2026-08-10
Results of Operations and Financial Condition. On August 10, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilit…
Why it matters: Completing enrollment is key for the timeline to pivotal results. This supports the company's growth plans.
Supportive ifThe PROACT 1 trial finished enrolling about 470 patients in 2026.
Worry ifEnrollment is delayed beyond the second half of 2026.
Why it matters: The result of this lawsuit could affect the company's future and funding.
Worry ifThere are good updates or a resolution in the lawsuit that help the company.
Less concerning ifBad news in the lawsuit could hurt the company's future.
Why it matters: Having cash reserves is important. It helps pay for studies and operations.
Worry ifManagement says cash reserves will last until mid-2027 without more funding.
Less concerning ifManagement says more funding is needed before mid-2027.
Why it matters: Cash levels affect how the company funds its operations. Falling below $150 million is a worry.
Worry ifCash and cash-like assets are over $150 million.
Less concerning ifCash reserves fall below $150 million.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$263 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $784 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,970 loss on $10,000 · 59.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: These results will determine the potential approval pathway for rilparencel. They are crucial for the company's future.
Supportive ifTopline results for the eGFR slope from the PROACT 1 trial are reported as anticipated in Q2 2027.
Worry ifTopline results are delayed beyond Q2 2027.
Why it matters: A revenue increase would show progress in growing sales, which is a key priority.
Supportive ifQuarterly revenue was over $230K. This shows a good growth trend.
Worry ifQuarterly revenue remains at or below $226K, showing no growth.
Why it matters: Cutting losses is key for keeping investor trust and funding.
Supportive ifOperating losses were less than -$40M. This shows better cost control.
Worry ifOperating losses remain at or worsen beyond -$44.9M, showing continued cash burn.
Why it matters: Updates on cash reserves will show if ProKidney can keep running until mid-2027.
Worry ifCash and equivalents were over $200 million in Q2 earnings.
Less concerning ifCash and equivalents were under $200 million. This raises worries about funding.
Why it matters: Tracking losses helps check financial health and how well the company operates.
Worry ifOperating losses decrease from $42.6 million in Q1 2026 to below $40 million in the next quarter.
Less concerning ifOperating losses increase or stay above $42.6 million in the next quarter.